2142 Stock Overview
A clinical-stage biopharmaceutical company, engages in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
HBM Holdings Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$1.34 |
| 52 Week High | HK$1.95 |
| 52 Week Low | HK$1.01 |
| Beta | 1.56 |
| 1 Month Change | 4.69% |
| 3 Month Change | 8.06% |
| 1 Year Change | -14.65% |
| 3 Year Change | -83.80% |
| 5 Year Change | n/a |
| Change since IPO | -87.84% |
Recent News & Updates
Recent updates
Investors Still Aren't Entirely Convinced By HBM Holdings Limited's (HKG:2142) Revenues Despite 30% Price Jump
Oct 02
Not Many Are Piling Into HBM Holdings Limited (HKG:2142) Just Yet
Jul 18HBM Holdings (HKG:2142) Seems To Use Debt Quite Sensibly
May 23Take Care Before Jumping Onto HBM Holdings Limited (HKG:2142) Even Though It's 28% Cheaper
Apr 12HBM Holdings Limited (HKG:2142) Surges 25% Yet Its Low P/S Is No Reason For Excitement
Jan 01We're Not Very Worried About HBM Holdings' (HKG:2142) Cash Burn Rate
Feb 08HBM Holdings (HKG:2142) Is In A Strong Position To Grow Its Business
May 30Revenue Downgrade: Here's What Analysts Forecast For HBM Holdings Limited (HKG:2142)
Apr 07Here's What Analysts Are Forecasting For HBM Holdings Limited (HKG:2142) After Its Full-Year Results
Mar 31What Type Of Shareholders Own The Most Number of HBM Holdings Limited (HKG:2142) Shares?
Mar 10Shareholder Returns
| 2142 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | 15.5% | -5.2% | -2.2% |
| 1Y | -14.6% | -5.3% | 18.3% |
Return vs Industry: 2142 underperformed the Hong Kong Biotechs industry which returned -5.3% over the past year.
Return vs Market: 2142 underperformed the Hong Kong Market which returned 18.3% over the past year.
Price Volatility
| 2142 volatility | |
|---|---|
| 2142 Average Weekly Movement | 9.4% |
| Biotechs Industry Average Movement | 11.0% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in HK Market | 18.7% |
| 10% least volatile stocks in HK Market | 4.1% |
Stable Share Price: 2142 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 2142's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 182 | Jingsong Wang | www.harbourbiomed.com |
HBM Holdings Limited, a clinical-stage biopharmaceutical company, engages in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. The company has developed the Harbour Mice Platform, which generates fully human monoclonal antibodies in the classical two heavy and two light chain H2L2 and heavy chain formats. It is developing Batoclimab (HBM9161), a human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor; HBM7008, a bispecific antibody targeting tumor Associated antigen; HBM4003, a human anti-CTLA-4 antibody against cytotoxic T-lymphocyte-associated antigen-4; and HBM1020, human monoclonal antibody generated from harbour mice platform targeting B7H7.
HBM Holdings Limited Fundamentals Summary
| 2142 fundamental statistics | |
|---|---|
| Market cap | HK$944.91m |
| Earnings (TTM) | HK$165.47m |
| Revenue (TTM) | HK$560.98m |
5.9x
P/E Ratio1.7x
P/S RatioIs 2142 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2142 income statement (TTM) | |
|---|---|
| Revenue | US$72.21m |
| Cost of Revenue | US$3.20m |
| Gross Profit | US$69.01m |
| Other Expenses | US$47.71m |
| Earnings | US$21.30m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.029 |
| Gross Margin | 95.57% |
| Net Profit Margin | 29.50% |
| Debt/Equity Ratio | 52.9% |
How did 2142 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 16:44 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
HBM Holdings Limited is covered by 7 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Bo Li | BofA Global Research |
| Tony Ren | CLSA |
| null null | Credit Suisse |